Mallinckrodt announces positive data for acthar gel in multiple sclerosis relapse patients

Mallinckrodt announces positive top-line findings from its observational registry assessing relapse recovery in multiple sclerosis relapse patients treated with acthar® gel (repository corticotropin injection).mallinckrodt plc - response was sustained at 6 months.mallinckrodt plc - results for main subsets of patients are highly statistically significant for all efficacy endpoints.mallinckrodt plc - analysis showed patients treated with acthar gel reported significant improvements in their ms relapse symptoms.mallinckrodt plc - results for main subsets of patients are highly statistically significant for all efficacy endpoints.mallinckrodt plc - adverse events were consistent with those in previous trials of acthar gel.
MNK Ratings Summary
MNK Quant Ranking